Chemotherapy in Prostate Cancer

Abstract

For approximately a decade, chemotherapy has been shown to prolong life in patients with metastatic castration-resistant prostate cancer (mCRPC). Since that time, however, only two agents have proven to prolong life (docetaxel and cabazitaxel). However, in the last year, the addition of chemotherapy to primary hormonal therapy became a standard of care for high-volume castration-sensitive metastatic disease. Here I will review current prostate cancer chemotherapies, mechanisms of resistance to those therapies, and ongoing clinical studies of chemotherapy combinations and novel chemotherapeutics.

Mechanism of dihydroartemisinin-induced apoptosis in prostate cancer PC3 cells: An iTRAQ-based proteomic analysis

“…Although the clinical outcome has improved, most patients with advanced PCa treated with HT eventually relapse and they develop castration-resistant PCa (CRPC) [11,12]. CRPC could be treated with sipuleucel-T, docetaxel, cabazitaxel, or abiraterone acetate plus prednisone, which was shown to prolong the survival in patients; however, CRPC is generally incurable [10][11][12][13][14]. There is therefore an urgent need for novel therapeutic strategies for CRPC.…”

Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer

“…1, 2), an advanced form of prostate cancer that develops when the disease progresses after initial treatment with surgery and/or medical castration using androgen deprivation therapy (ADT). Docetaxel and cabazitaxel are 2 taxane chemotherapies that are approved for treatment of metastatic CRPC (3). Recent studies have reported benefits when docetaxel was combined with ADT during the hormone-sensitive stage of the disease (3,4).…”

Glyceryl trinitrate‑induced cytotoxicity of docetaxel‑resistant prostatic cancer cells is associated with differential regulation of clusterin

“…androgen deprivation therapy reduces tumor progression, relapse frequently occurs following surgical or chemical castration. Over a decade, docetaxel is the first-line systemic chemotherapy used for metastatic castration-resistant prostate cancer (mCRPC) (2).…”